|Bid||112.93 x 100|
|Ask||113.47 x 100|
|Day's Range||112.40 - 115.04|
|52 Week Range||31.38 - 118.40|
|PE Ratio (TTM)||-22.44|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Q2 2017 Alnylam Pharmaceuticals Inc Earnings Call
Why Madrigal, Alnylam, and Arbutus Biopharma stocks were this week's biggest biotech winners.
Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.